SEIPASA

Seipasa is a leading company specialized in natural treatments for agriculture. Seipasa is pioneer in researching, manufacturing and marketing biopesticides, biostimulants and fertilizers. The company has been working for 20 years in natural protection of crops and plant biostimulation based on solutions of botanical origin. From its headquarters in Valencia, Spain, and conducted by the R&D department, the company formulates and certificates solutions of high technological value which are applied in the most demanding agricultures of the world. Seipasa is stablished in over 20 countries worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

CONTROLANT NOW PROVIDING MONITORING AND SUPPLY CHAIN VISIBILITY FOR PFIZER-BIONTECH COVID-19 VACCINE'S GLOBAL DISTRIBUTION

Controlant | December 16, 2020

news image

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant ...

Read More

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

news image

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More

CELL AND GENE THERAPY

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

news image

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More

CELL AND GENE THERAPY

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

news image

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More
news image

MEDICAL

CONTROLANT NOW PROVIDING MONITORING AND SUPPLY CHAIN VISIBILITY FOR PFIZER-BIONTECH COVID-19 VACCINE'S GLOBAL DISTRIBUTION

Controlant | December 16, 2020

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant ...

Read More
news image

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More
news image

CELL AND GENE THERAPY

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More
news image

CELL AND GENE THERAPY

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More